Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Vedanta’s Risky Diversification into JP Associates;Instead of Debt Reduction

The Beat Ideas: Vadilal Industries - Will Professional Management Improve Operational Excellence?

Kiri’s $700 Million Exit From DyStar – What Next?

Thematic Report on Indian Hospitals - Boring but Beautiful?

The Beat Ideas: Enviro Infra Engineers Ltd - High-Margin Growth Story in Water Infra

Business Breakdown: Kovai Medical - A Regional Leader in a Growing National Market

Thematic Report: Shipbuilding, Largest Opportunity in India

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>The company operates a diversified portfolio of sterile liquid products across six therapeutic segments, with a strong domestic presence and expanding global reach, ensuring consistent revenue streams. </li>
<li>Proceeds from the IPO will fund the establishment of two new sterile manufacturing lines, significantly enhancing SteriPort and SVP capacities, expected to drive growth in FY26-27. </li>
<li>While the IPO valuation appears elevated at 46x FY25earnings, the company’s debt reduction and expanded capacity should lead to moderated multiples.</li>
</ul>


The company operates a diversified portfolio of sterile liquid products across six therapeutic segments, with a strong domestic presence and expanding global reach, ensuring consistent revenue streams. 
Proceeds from the IPO will fund the establishment of two new sterile manufacturing lines, significantly enhancing SteriPort and SVP capacities, expected to drive growth in FY26-27. 
While the IPO valuation appears elevated at 46x FY25earnings, the company’s debt reduction and expanded capacity should lead to moderated multiples.


The Beat Ideas: Amanta Healthcare IPO - 無菌医薬品分野での成長の舵取り。